Fig. 1 · Structure
Documents & Downloads
Trastuzumab duocarmazine
HER2-targeted ADC
Trastuzumab duocarmazine is a HER2-targeted antibody-drug conjugate (ADC) that exhibits selective cytotoxicity towards tumor cells. The compound is recognized and cleaved by histone B within cancer cells, leading to its potent anti-tumor activity. This reagent is particularly useful for research applications focused on uterine and ovarian sarcomas, providing insights into effective therapeutic strategies against HER2-positive malignancies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1642152-40-6 |
| Applications | HER2-targeted ADC |
| Molecular Weight | 149000 (average) |
| Synonyms | (vic)-Trastuzumab duocarmazine |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.